EUCTR2011-003314-16-HU进行中（未招募）不适用
A Randomized, Active Controlled, Double-blind, Multi-Centre Study to Evaluate Safety and Immunogenicity of One Dose of FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccine Containing 6µgHA of Seasonal A/H1N1, A/H3N2 and B Influenza Antigens in Non-elderly Adult and Elderly Subjects
Omninvest Ltd.0 个研究点开始时间: 2011年7月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects eligible for enrolment into this study are:
- •- male and female adult volunteers aged 18 years or older,
- •- mentally competent,
- •- able to understand and comply with all study requirements,
- •- willing and able to give written informed consent prior to initiation of study procedures,
- •- in good health (as determined by clinical judgement of the investigator on the basis of medical history and existing medical condition) or are in stable medical condition. Subjects will not be excluded with known, adequately treated, clinically significant organ or systemic diseases (e.g. asthma or diabetes), such that, in the opinion of the investigator, the significance of the disease will not compromise the subject's participation in the study.
- •Female subjects aged 18 to 60 years (i.e. participants of childbearing potential) with a negative result from the urine pregnancy test prior to vaccination who agrees to use an acceptable contraception method or abstinence throughout the trial and not become pregnant for the duration of the study.
- •Absence of existence of any exclusion criteria.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 504
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 728
排除标准
- •Pregnancy, breast-feeding or positive urine pregnancy test at baseline prior to vaccination. Female subjects who are able to bear children but not willing to use an acceptable contraception method for the duration of the study.
- •Hypersensivity to eggs, chicken protein, thiomersal, formaldehyde, gentamycin, ciprofloxacin, neomycin or any other component of the vaccine;
- •History of anaphylactic shock or neurological symptoms or signs following administration of any vaccine;
- •History of Guillain-Barré syndrome;
- •Serious disease, such as cancer, autoimmune disease, advanced arteriosclerotic disease, complicated diabetes mellitus, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure;
- •Immunosuppressive therapy within the past 36 months;
- •Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids;
- •Receipt of immunostimulants;
- •Receipt of parenteral immunoglobulin, blood products and/or plasma derivates within the past 3 months;
- •Suspected or known HIV, HBV or HCV infection;
- •Acute disease and/or axillary temperature =37oC within the past 3 days;
- •Vaccine therapy within the past 4 weeks;
- •Influenza vaccination (any kind) within the past 6 months;
- •Experimental drug therapy within the past 4 weeks;
- •Concomitant participation in another clinical study;
- •Any condition which, in the opinion of the investigator, may interfere with the evaluation of the study;
- •Past or current psychiatric disease of the subject that upon judgement of the investigator may have effect on the objective decision-making of the subject;
- •Alcohol or drug abuse of the subject.
研究者
相似试验
已完成
不适用
Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 in Patients with Dyslipidemia and HypertensioKCT0006283Addpharma105
已完成
3 期
The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.CTRI/2010/091/006067Johnson and Johnson Ltd720
进行中（未招募）
不适用
The study is to evaluate the effectiveness and safety of switching to coadministration ezetimibe and atorvastatin compared with doubling the dose of atorvastatin or switching to rosuvastatin in patients with primary hypercholesterolemia and high cardiovascular risk who are not adequately controlled with atorvastatin 10 mg. Ezetimibe, atorvastatin and rosuvastatin are each available by prescription to treat high blood cholesterol levels.Primary HypercholesterolemiaMedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2009-015247-16-EEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,508
进行中（未招募）
不适用
The study is to evaluate the effectiveness and safety of switching to coadministration ezetimibe and atorvastatin compared with doubling the dose of atorvastatin or switching to rosuvastatin in patients with primaryhypercholesterolemia and high cardiovascular risk who are not adequately controlled with atorvastatin 10 mg.Ezetimibe, atorvastatin and rosuvastatin are each available by prescription to treat high blood cholesterol levels.Primary HypercholesterolemiaMedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2009-015247-16-BGMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,508
进行中（未招募）
不适用
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin (10mg/20mg) Versus Switching to Rosuvastatin 10mg or Doubling the Statin Doseipids not at goal in diabetic patients with cardiovascular diseaseEUCTR2008-007689-52-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.800